- Patented technology promotes healthier administration of active pharmaceutical ingredients, including cannabidiol (CBD), psychoactive cannabinoids (THC), nicotine, fat soluble vitamins and nonsteroidal anti-inflammatory drugs
- Active pharmaceutical ingredient market expected to exceed $239 billion by 2025
- 19 patent applications filed in U.S. and internationally encompassing 44 countries
- Lab tests in 2018 include topical CBD skin cream, nicotine in edible formats
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://ibn.fm/iaAZ9), the global API market is anticipated to reach $239.8 billion by 2025, with a CAGR of six percent. The rising prevalence of chronic health issues such as neurological and cardiovascular diseases are identified as growth factors.
Lexaria recently received a broad-ranging U.S. patent award for DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients. The U.S. patent covers all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine (http://ibn.fm/yOK2Q). LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty) and national filings in 44 countries.
“Lexaria has now locked-up the IP for its next-generation drug delivery system,” Chief Executive Officer Chris Bunka said in a news release announcing the U.S. patent award (http://ibn.fm/jl69G). “This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world’s first nicotine edibles for the smokeless tobacco industry, or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market.”
Through the application of Lexaria’s revolutionary DehydraTECH™ platform to specific compounds in the cannabis plant, for instance, issues such as bad taste, delay of onset, unwanted side effects and poor absorption are eliminated. Lexaria’s technology transforms the way cannabinoids enter the bloodstream through the gastrointestinal tract, providing a fast-acting, tasteless product with increased bioavailability. The company’s innovative technology solves multiple problems and offers third-party partners and distributors the ability to focus on creating safe, standardized products with mass appeal (http://ibn.fm/JZxyy).
Regulations affecting the legal cannabis industry in the U.S. and Canada underscore the need for DehydraTECH™ and its commercial application potential for edible cannabinoid products. Smoking cannabis is prohibited or limited to specific locations, and there are regulations governing the appearance and amount of psychoactive compounds allowed in edible cannabis products (http://ibn.fm/15z6D). Regulations governing the rapidly changing cannabis industry, along with market trends, increase the need for fast-acting, high-absorption, alternative delivery methods – which is Lexaria’s specific focus.
While 2017 was a transformative year for Lexaria, the company expects 2018 to be even more significant for its shareholders as testing commences with DehydraTech™ in nicotine edibles and a topical skin cream infused with cannabinoids. The company’s strategic focus is on out-licensing DehydraTECH™ to third-party partners using a high margin royalty model. Lexaria’s first licensee in the edible cannabis space is a chocolate/cannabis company located in Colorado. Advanced discussions are also underway with additional U.S. edibles manufacturers that range from $5 million to $50 million in annual sales.
President John Docherty is slated to discuss the company’s strategic partnerships and the necessity of focused business models such as the ones guiding Lexaria during the International Cannabis Business Conference scheduled February 1-2 in San Francisco.
For more information, visit the company’s website at www.LexariaEnergy.com
Let us hear your thoughts: Lexaria Bioscience Corp. Message Board
